Please ensure Javascript is enabled for purposes of website accessibility

Cathie Wood Couldn't Stop Buying These 3 Stocks for ARK Invest Last Week

By Dan Caplinger - Updated Feb 23, 2021 at 8:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's what the star investor has done recently.

The hottest person in the usually quiet world of exchange-traded funds  is Cathie Wood. Her ARK Invest actively managed ETFs have been a pioneering force in the industry, and the fact that they all doubled in price in 2020 was a huge selling point.

Wood is constantly buying and selling stocks for her five main active ETFs. However, three companies in particular really stood out last week, given the size and persistence of Wood's purchasing activity. Let's look at these companies and see whether they look like solid picks right now.

Computer screens with graphs and charts.

Image Source: Getty Images.

1. Palantir Technologies

Palantir Technologies (PLTR 5.43%) was a big buy from Wood last week. Her flagship ARK Innovation ETF (ARKK 4.64%) bought more than 5.27 million shares of the data analytics specialist's stock on Feb. 18, making up about half a percent of the ETF's total holdings. That followed a Feb. 16 purchase of 1.56 million shares for the ARK Next-Generation Internet ETF (ARKW 4.88%), representing roughly the same 0.5% buy. That adds up to almost $200 million in purchases.

The big Feb. 18 buy came immediately after Palantir reported its quarterly financials, which sent the stock sharply lower and gave Wood a bargain entry point. Some investors were nervous that although Palantir's revenue jumped 40% year over year, it contained to lose money at a higher rate than most had anticipated. Yet as with many young companies, Palantir had a lot of stock-based compensation to weigh on its bottom line. Back that out, and there were encouraging things to see, including improving margins and considerable growth in its nongovernment private-sector business.

I'd anticipate that Wood will continue to add to positions in Palantir at opportunistic moments. It's one of ARK Innovation's smallest positions, but that could change quickly based on her past practice.

2. Tesla

Tesla (TSLA 4.88%) has been the driving force behind Wood's success over the past year, and the electric-vehicle maker's stock is a top holding across several ARK Invest ETFs. Wood remains optimistic about the Elon Musk-led company's future success.

Specifically, Wood bought a total of nearly 162,000 shares for ARK Innovation on Feb. 17 and Feb. 19, spending almost half a percent of assets. She bought a bit over 29,500 shares for ARK Next-Generation Internet and almost 13,200 shares for ARK Autonomous Technology & Robotics (ARKQ 1.80%), working out to roughly 0.25% of assets for both funds. All told, she likely spent around $160 million to bring holdings of Tesla in those three ETFs to between 8% and 10% each.

Wood likes Tesla not just for its fast-growing dominant EV franchise but also for adjacent opportunities in areas like autonomous driving, artificial intelligence, and battery technology. Last week, she mentioned ride-sharing as a potential use for Tesla vehicles as well. Wood isn't giving up on the horse that helped her win the race in 2020, and many investors also remain optimistic on the stock's prospects.

3. AbbVie

Finally, AbbVie (ABBV 1.91%) was a big favorite for the ARK Genomic Revolution ETF (ARKG 1.91%). Wood made successive purchases of 122,000, 295,000, and 186,000 shares on Feb. 16, 17, and 18, adding up to about 0.5% of the ETF's assets. The genomics ETF is smaller than its peers, so that amounted to spending of around $60 million.

Two of ARK Invest's big ideas for 2021 involve multi-cancer screening and second-generation cell and gene therapies. Many of the companies held by the genomics ETF are newer players in the field, such as top holding Teladoc Health (TDOC 2.56%). However, AbbVie has a massive pipeline of candidate treatments along with a solid balance sheet for potential acquisitions and strategic partnerships. Wood apparently believes that AbbVie is well-positioned to take advantage of what she sees as groundbreaking trends in the healthcare space.

Don't take your eyes off Cathie Wood's stock picks

With so many investors watching Cathie Wood's investment moves in her red-hot actively managed ETFs, it's essential to know the big moves she's making. Her opinions carry a huge amount of weight, and she can serve as a useful source of ideas if you're looking for stocks to add to your portfolio.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tesla, Inc. Stock Quote
Tesla, Inc.
TSLA
$658.80 (4.88%) $30.64
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$151.96 (1.91%) $2.85
Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
TDOC
$31.66 (2.56%) $0.79
ARK ETF Trust - ARK Innovation ETF Stock Quote
ARK ETF Trust - ARK Innovation ETF
ARKK
$41.03 (4.64%) $1.82
ARK ETF Trust - ARK Next Generation Internet ETF Stock Quote
ARK ETF Trust - ARK Next Generation Internet ETF
ARKW
$53.03 (4.88%) $2.47
ARK ETF Trust - ARK Genomic Revolution ETF Stock Quote
ARK ETF Trust - ARK Genomic Revolution ETF
ARKG
$31.50 (1.91%) $0.59
Palantir Technologies Inc. Stock Quote
Palantir Technologies Inc.
PLTR
$7.96 (5.43%) $0.41
ARK ETF Trust - ARK Autonomous Technology & Robotics ETF Stock Quote
ARK ETF Trust - ARK Autonomous Technology & Robotics ETF
ARKQ
$51.47 (1.80%) $0.91

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
322%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.